Kia Akrami

With over 15 years in bio-manufacturing—spanning academia and industry, from lab-scale to pharmaceutical-grade production—we’ve faced a hard truth: biomanufacturing isn’t "sexy"… until it saves your program. We’ve worked with biologics like viral vectors, monoclonal antibodies, and nucleic acids, uncovering critical gaps—delays, missed details, and reactive fixes—that cost time, money, and breakthroughs. In an investor climate obsessed with fast returns, manufacturing is often overlooked, leaving patients waiting and investors at risk. That’s why we launched Enzymatic Minds Inc. With AI-smart solutions and human-powered precision, honed through thousands of runs, we flip the script. We make manufacturing proactive and powerful, turning science into therapies that reach patients and deliver returns investors trust. Because robust bio-manufacturing isn’t just the backbone—it’s the breakthrough.